This afternoon we watched Cencora drop -4.2% to a price of $227.28 per share. The Large-Cap Pharmaceutical company is now trading -12.17% below its average target price of $258.78. Analysts have set target prices ranging from $229.0 to $280.0 per share for Cencora, and have given the stock an average rating of buy.
Cencora has an average level of shares sold short, at 6.5% of its total share float. The stock's short ratio (also called days to cover) is 6.42. The company's insiders own 13.48% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 88.5% of Cencora's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Cencora
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Walgreens Boots Alliance, Inc. | 13% | 26,277,561 | $5,972,364,032 |
| 2024-03-31 | Vanguard Group Inc | 10% | 20,348,522 | $4,624,812,055 |
| 2024-03-31 | Blackrock Inc. | 10% | 19,197,966 | $4,363,313,689 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 5% | 8,986,455 | $2,042,441,481 |
| 2024-03-31 | State Street Corporation | 4% | 7,921,778 | $1,800,461,694 |
| 2024-03-31 | FMR, LLC | 3% | 5,455,887 | $1,240,013,990 |
| 2024-03-31 | Wellington Management Group, LLP | 3% | 5,015,230 | $1,139,861,468 |
| 2024-03-31 | JP Morgan Chase & Company | 2% | 4,937,221 | $1,122,131,582 |
| 2023-12-31 | Boston Partners | 2% | 4,032,600 | $916,529,323 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 3,918,579 | $890,614,630 |
